Rapport Therapeutics, Inc. (RAPP)
NASDAQ: RAPP · Real-Time Price · USD
22.19
-0.09 (-0.40%)
Nov 20, 2024, 4:00 PM EST - Market closed
Rapport Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Selling, General & Admin | 18.79 | 8.18 | 1.37 |
| Research & Development | 55.54 | 28 | 4.49 |
| Operating Expenses | 74.33 | 36.18 | 5.85 |
| Operating Income | -74.33 | -36.18 | -5.85 |
| Interest Expense | - | - | -0.31 |
| Interest & Investment Income | 9.97 | 2.53 | - |
| EBT Excluding Unusual Items | -64.36 | -33.65 | -6.17 |
| Other Unusual Items | -7.48 | -1.12 | - |
| Pretax Income | -71.84 | -34.78 | -11.62 |
| Income Tax Expense | 0.01 | 0.01 | - |
| Net Income | -71.85 | -34.79 | -11.62 |
| Net Income to Common | -71.85 | -34.79 | -11.62 |
| Shares Outstanding (Basic) | 12 | 2 | 1 |
| Shares Outstanding (Diluted) | 12 | 2 | 1 |
| Shares Change (YoY) | 1491.15% | 93.74% | - |
| EPS (Basic) | -5.81 | -23.10 | -14.95 |
| EPS (Diluted) | -5.81 | -23.10 | -14.95 |
| Free Cash Flow | -64.36 | -28.82 | -3.85 |
| Free Cash Flow Per Share | -5.20 | -19.14 | -4.95 |
| EBITDA | -73.7 | -36.07 | -5.84 |
| D&A For EBITDA | 0.63 | 0.11 | 0.02 |
| EBIT | -74.33 | -36.18 | -5.85 |
Source: S&P Capital IQ. Standard template.
Financial Sources.